MHRA’s GXP data integrity guide published – March 2018

After the British agency MHRA has published three (3) different draft versions of the – MHRA GMP Data Integrity Definitions and Guidance for Industry – in January and March 2015 (GMP) and in July 2016 (Draft for consultation – now for GXP) the final  “Medicines & Healthcare products Regulatory Agency (MHRA) ‘GXP’ Data Integrity Guidance and Definitions was published in March 2018.

Looking into the history of the document and content the major changes have been to replace and extend from “GMP” to GXP (covering  GCP, GDP, GLP, GMP and GPvP).  All this GXP areas had already requirements for data integrity or study integrity or similar for many years and are covered by European EMA regulations, directives and the EMA EudraLex Volumes or other regulations (e.g. chemical for GLP). The second change was the title “Guidance for Industry” to a “Guide“. Maybe the document type “Guidance for Industry” would remind you to US regulations and you are right. But in the EU such a document type in a regulatory structure and understanding is also not known. Maybe the roots of the first versions were coming from US or consultants or authors from this region. In general an own opinion might be better as to listen to any opinion-makers with commercial interests. Continue reading “MHRA’s GXP data integrity guide published – March 2018”

QP Update 2018 – Mannheim, Germany – 19./20. April 2018

Das Seminar wendet sich an alle Sachkundige Personen/ QPs. Ebenfalls angesprochen sind Leiter und Mitarbeiter von Qualitätsmanagement und Qualitätssicherung und Mitglieder der Unternehmensleitung, die einen umfassenden Überblick über Pflichten und Aufgaben der sachkundigen Personen/QPs erhalten mochten:

Qualified Person Update 2018 – Neues für die Sachkundige Person in Deutschland;   19./20. April 2018, Mannheim

Zum Online – Programm…

Continue reading “QP Update 2018 – Mannheim, Germany – 19./20. April 2018”

Microsoft Azure GXP Guideline now published – reviewed by CCS

The goal of this GXP guidelines document is to provide life sciences organizations with a comprehensive toolset for using Microsoft Azure while adhering to industry best practices and applicable regulations. It identifies the shared responsibilities between Microsoft and its life sciences customers for meeting regulatory requirements, such as US-FDA 21 CFR Part 11 Electronic Records, Electronic Signatures (21 CFR Part 11), and EudraLex Volume 4 – Annex 11 Computerised Systems (EMA Annex 11).

Microsoft Azure GxP Guidelines – 06.12.2017 – Download

Events 2018: How to validate Software Development tools used for GXP and MedDev?

8 February 2018, Stuttgart, Germany (9 am to 5 pm)

Venue: Milaneo Office Center, Heilbronner Straße 74, Stuttgart, Germany

The programme will focus on regulated companies that are in the process of the implementation and validation of software development tools like JIRA, BitBucket and Confluence (Atlassian). If such tools are used for GXP activities (GMP, GLP, GDP, GVP, GCP) or medical devices (MedDev) these must comply with regulations like 21 CFR Part 211, Part 820, Part 11 or EMA EudraLex Vol. 4 – Annex 11.

Several standards and guidelines might be applied to the design of the software development lifecycle (SDLC) and the validation of software, like ISPE GAMP, ISO 12207, IEC 62304, CMMI and AAMI TIR45:2012.

This conference covers regulations, standards, examples and solutions!

The event can also be found on XING Event Plus – OPEN LINK.

Register online here.

Continue reading “Events 2018: How to validate Software Development tools used for GXP and MedDev?”

EU-US mutual recognition of inspections

1 November 2017 marks the coming into operation of further aspects of the mutual recognition agreement between the European Union (EU) and the United States (US) to recognise inspections of manufacturing sites for human medicines conducted in their respective territories. This agreement, which updates the agreement from 1998, allows for recognition of each other’s inspection outcomes and hence for better use of inspection expertise and resources.

Read more:

  • EMA Press Release
  • Third QP conference: QP challenges in modern pharmaceutical trading; 29. / 30. September 2017, Belgrade

    The Conference is designed for all Qualified Persons and aspiring Qualified Persons. It also addresses upper management functions and authority representatives who want to be informed about the latest development regarding the duties and responsibilities of Qualified Persons.

    29. and 30. September 2017
    Venue Best Western Hotel M 56a Bulevar Oslobođenja Street, Belgrade

    Read more: http://www.pharmacy.bg.ac.rs/files/Doga%C4%91aji/2017/QP%20konferencija/flajer%20engleski%202017.pdf

    US-FDA: Use of Electronic Records and Electronic Signatures in Clinical Investigations Under Part 11— Questions and Answers; Draft Guidance for Industry

    The US FDA Agency  was announcing the availability of a draft guidance for industry entitled ‘‘Use of Electronic Records and Electronic Signatures in Clinical Investigations under our regulations—Questions and Answers.’’ The draft guidance provides guidance to sponsors, clinical investigators, institutional review boards (IRBs), contract research organizations (CROs), and other interested parties on the use of electronic records and electronic signatures under our regulations in clinical investigations of medical products.

    Download: Use of Electronic Records and Electronic Signatures in Clinical Investigations Under Part 11— Questions and Answers; Draft Guidance for Industry